Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients.

IF 1.3 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Biomedical Research-tokyo Pub Date : 2022-01-01 DOI:10.2220/biomedres.43.115

Yuji Shimoda, Takeshi Nagashima, Kenichi Urakami, Fukumi Kamada, Sou Nakatani, Maki Mizuguchi, Masakuni Serizawa, Keiichi Hatakeyama, Keiichi Ohshima, Tohru Mochizuki, Sumiko Ohnami, Shumpei Ohnami, Takeshi Kawakami, Kentaro Yamazaki, Haruyasu Murakami, Hirotsugu Kenmotsu, Akio Shiomi, Yasuto Akiyama, Ken Yamaguchi

{"title":"Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients.","authors":"Yuji Shimoda, Takeshi Nagashima, Kenichi Urakami, Fukumi Kamada, Sou Nakatani, Maki Mizuguchi, Masakuni Serizawa, Keiichi Hatakeyama, Keiichi Ohshima, Tohru Mochizuki, Sumiko Ohnami, Shumpei Ohnami, Takeshi Kawakami, Kentaro Yamazaki, Haruyasu Murakami, Hirotsugu Kenmotsu, Akio Shiomi, Yasuto Akiyama, Ken Yamaguchi","doi":"10.2220/biomedres.43.115","DOIUrl":null,"url":null,"abstract":"<p><p>Next-generation sequencing (NGS) is an integral part of precision medicine, and its power for detecting comprehensive genetic alterations may contribute to treatment decisions for patients with advanced, recurrent, or metastatic cancer. An NGS oncology panel developed in the U.S. and Europe, which targets cancer-related genes, has been approved in Japan, and testing is becoming more widespread in clinical oncology practice. However, these panels are based on cancer-related genes selected from cancer databases of Westerners. We aimed to develop an onco-panel for Japanese. We designed two High-tech Omics-based Patient Evaluation (HOPE) onco-panels: HOPE onco-panel Solid for solid tumors and HOPE onco-panel Liquid for liquid biopsy. These were based on genomic information of 5,143 cancer cases in the Japanese Cancer Genome Atlas (JCGA), a database of Japanese cancer cases. Their performance was confirmed using clinical data.</p>","PeriodicalId":9138,"journal":{"name":"Biomedical Research-tokyo","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Research-tokyo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2220/biomedres.43.115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 1

Abstract

Next-generation sequencing (NGS) is an integral part of precision medicine, and its power for detecting comprehensive genetic alterations may contribute to treatment decisions for patients with advanced, recurrent, or metastatic cancer. An NGS oncology panel developed in the U.S. and Europe, which targets cancer-related genes, has been approved in Japan, and testing is becoming more widespread in clinical oncology practice. However, these panels are based on cancer-related genes selected from cancer databases of Westerners. We aimed to develop an onco-panel for Japanese. We designed two High-tech Omics-based Patient Evaluation (HOPE) onco-panels: HOPE onco-panel Solid for solid tumors and HOPE onco-panel Liquid for liquid biopsy. These were based on genomic information of 5,143 cancer cases in the Japanese Cancer Genome Atlas (JCGA), a database of Japanese cancer cases. Their performance was confirmed using clinical data.

查看原文本刊更多论文

基于5143名日本癌症患者基因组数据的实体瘤和液体活检两种410种癌症基因面板测试的开发。

新一代测序(NGS)是精准医学的一个组成部分，其检测全面基因改变的能力可能有助于晚期、复发或转移性癌症患者的治疗决策。在美国和欧洲开发的针对癌症相关基因的NGS肿瘤小组已在日本获得批准，并且在临床肿瘤实践中越来越普遍。然而，这些小组是基于从西方人的癌症数据库中选择的癌症相关基因。我们的目标是为日本人开发一个联合面板。我们设计了两个基于高科技组学的患者评估(HOPE)肿瘤组:用于实体肿瘤的HOPE固体肿瘤组和用于液体活检的HOPE液体肿瘤组。这些结论是基于日本癌症病例数据库——日本癌症基因组图谱(JCGA)中5143例癌症病例的基因组信息。临床数据证实了它们的性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical Research-tokyo 医学-医学：研究与实验

CiteScore

2.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Biomedical Research is peer-reviewed International Research Journal . It was first launched in 1990 as a biannual English Journal and later became triannual. From 2008 it is published in Jan-Apr/ May-Aug/ Sep-Dec..